Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype

被引：0
|
作者：
Marotta, G [1 ]
Bigazzi, C [1 ]
Bocchia, M [1 ]
Forconi, F [1 ]
Lauria, F [1 ]
机构：
[1] Univ Siena, A Sclavo Hosp, Div Hematol, I-53100 Siena, Italy
来源：
HAEMATOLOGICA | 1998年 / 83卷 / 09期
关键词：
non Hodgkin lymphoma; ProMACE-CytaBOM regimen; long-term follow-up;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were evaluated. Twenty-four out of 54 (45%) patients achieved a complete remission and 13 of them are still in continuous remission with a median survival of 53.5 months. Interestingly, in 16 patients with intermediate grade histology we obtained an overall response rate of 100%.
引用
收藏
页码：853 / 854
页数：2
相关论文
共 50 条
  • [1] LONG-TERM FOLLOW-UP OF PROMACE-CYTABOM IN NON-HODGKINS-LYMPHOMAS
    FISHER, RI
    LONGO, DL
    DEVITA, VT
    HUBBARD, SM
    MILLER, TP
    YOUNG, RC
    ANNALS OF ONCOLOGY, 1991, 2 : 33 - 35
  • [2] CHOP vs ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: Long-term results of a multicenter randomized trial
    Montserrat, E
    GarciaConde, J
    Vinolas, H
    LopezGuillermo, A
    HernandezNieto, L
    Zubizarreta, A
    Maldonado, J
    Alcala, A
    Faura, MV
    Llorente, A
    Blade, J
    Fontanillas, M
    Estape, J
    Rozman, C
    GonzalezBrito, C
    Conde, E
    Pascual, A
    SanchezManzano, C
    Giral, M
    Moro, MJ
    Ramos, F
    MacroVera, J
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 57 (05) : 377 - 383
  • [3] Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
    Rossini, F
    Terruzzi, E
    Perego, D
    Miccolis, I
    Rivolta, F
    Manca, E
    Pogliani, EM
    CANCER, 2004, 100 (02) : 350 - 355
  • [4] LONG-TERM FOLLOW-UP OF CHOP-TREATED NON-HODGKIN LYMPHOMA OF HIGH-GRADE MALIGNANCY
    HEINZ, R
    BLUT, 1990, 60 (02): : 68 - 75
  • [5] A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
    Witzig, TE
    Camoriano, JK
    Schroeder, G
    Kurtin, PJ
    Habermann, TM
    LEUKEMIA & LYMPHOMA, 1998, 28 (3-4) : 307 - 314
  • [6] Long term follow up of the patients with non-Hodgkin's Lymphoma treated with Rituximab in combination with CHOP regimen.
    Li, JM
    BLOOD, 2005, 106 (11) : 274B - 274B
  • [7] Long-Term Follow-Up of Patients with Non-Hodgkin and Hodgkin Lymphomas with a Modified BEAM Conditioning Regimen
    Armillas, Flor
    Leon, Eucario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S251 - S251
  • [8] Primary non-Hodgkin's malignant lymphoma of the breast: long-term follow-up
    Imai, T
    Shiga, T
    BREAST, 2004, 13 (02): : 152 - 154
  • [9] THE NON-HODGKIN LYMPHOMA PATHOLOGIC CLASSIFICATION PROJECT - LONG-TERM FOLLOW-UP OF 1153 PATIENTS WITH NON-HODGKIN LYMPHOMAS
    SIMON, R
    DURRLEMAN, S
    HOPPE, RT
    BONADONNA, G
    BLOOMFIELD, CD
    RUDDERS, RA
    CHESON, BD
    BERARD, CW
    ANNALS OF INTERNAL MEDICINE, 1988, 109 (12) : 939 - 945
  • [10] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group
    Lorusso, V
    Palmieri, G
    Bianco, AR
    Abate, G
    Catalano, G
    De Vita, F
    Dammacco, F
    Lauta, VM
    Lucarelli, G
    Polimeno, G
    Mantovani, G
    D'Aprile, M
    Marzullo, F
    De Lena, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 16 (01) : 149 - 154
12345